Welcome to our dedicated page for Structure Therapeutics ADR news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics ADR stock.
Structure Therapeutics Inc. develops oral small-molecule therapeutics for chronic metabolic diseases, with a focus on obesity. The clinical-stage global biopharmaceutical company uses a structure-based drug discovery platform and GPCR-targeted pipeline to advance wholly owned compounds, including aleniglipron, an oral nonpeptide GLP-1 receptor agonist, and ACCG-2671, an oral amylin receptor agonist.
Recurring company updates include clinical data from the ACCESS aleniglipron program, obesity and weight-management research presentations, financial results, research-and-development funding, ADS and warrant financings, and leadership or governance changes. The company’s American depositary shares trade under GPCR, with each ADS representing three ordinary shares.
Structure Therapeutics (NASDAQ: GPCR) announced on December 8, 2025 the commencement of a proposed underwritten public offering to issue and sell $500 million of American depositary shares (ADSs) or, for certain investors, pre-funded warrants to purchase ordinary shares represented by ADSs. Each ADS represents three ordinary shares. The company expects to grant underwriters a 30-day option to purchase up to an additional $75 million of ADSs or pre-funded warrants. The offering is subject to market and other conditions and may not be completed. The offering is being made under an automatic shelf registration statement on Form S-3 filed with the SEC on August 6, 2025, and a preliminary prospectus supplement will be filed and available on SEC.gov.
Structure Therapeutics (NASDAQ: GPCR) reported positive 36‑week topline results for oral GLP‑1 receptor agonist aleniglipron from the ACCESS program supporting Phase 3 entry by mid‑2026. In the Phase 2b ACCESS study aleniglipron 120 mg produced a placebo‑adjusted mean weight loss of 11.3% (27.3 lbs) at 36 weeks (p<0.0001) with AE‑related discontinuations ranging 7.7%–13.3% (mean 10.4%) across active arms. In exploratory ACCESS II, the 240 mg dose achieved placebo‑adjusted mean weight loss up to 15.3% (35.5 lbs) at 36 weeks (p<0.0001). Studies reported GLP‑1 class GI adverse events, no drug‑induced liver injury, no persistent liver enzyme elevations, and no QTc prolongation. Company plans an FDA Type B meeting in H1 2026 and to start Phase 3 by mid‑2026.
Structure Therapeutics (NASDAQ: GPCR) will release topline data from its ACCESS clinical program of aleniglipron, a once-daily oral small-molecule GLP-1 receptor agonist for obesity, before market open on Monday, December 8, 2025. Management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day.
Investors can access the live webcast via the company Investor Relations events page and obtain phone dial-in details from the provided link. A replay will be posted approximately two hours after the live event and will remain available for 90 days.
Structure Therapeutics (NASDAQ: GPCR) reported that topline 36-week data from its oral GLP-1 agonist aleniglipron ACCESS and ACCESS II studies are on track for readouts by year-end 2025. The company expects to initiate a first-in-human Phase 1 study of oral amylin receptor agonist ACCG-2671 by year-end 2025 and has declared a second amylin candidate, ACCG-3535, with preclinical data showing dose-dependent weight loss and reduced food intake in rodent models.
Financials: cash, cash equivalents and short-term investments of $799.0 million as of September 30, 2025, projected to fund operations through at least 2027 (excludes Phase 3 registrational studies). Q3 2025 results: R&D $59.0M, G&A $14.8M, net loss $65.7M.
Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic diseases and obesity, has announced its participation in two major healthcare investor conferences.
Management will present at the Cantor Global Healthcare Conference on September 3 at 3:55 p.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 at 10:45 a.m. ET. Both events will be held in New York and will feature fireside chats along with one-on-one meetings. Webcasts will be available on the company's investor relations website for 90 days.
Structure Therapeutics (NASDAQ: GPCR) reported Q2 2025 financial results and clinical progress updates. The company's lead candidate aleniglipron, an oral GLP-1 receptor agonist, is advancing with topline data from ACCESS and ACCESS II studies expected by year-end 2025. The clinical program has been expanded with three additional studies to optimize competitive positioning.
The company maintains a strong financial position with $786.5 million in cash and investments, expected to fund operations through 2027. Q2 2025 saw increased R&D expenses of $54.7 million (vs $22.1M in Q2 2024) and a net loss of $61.7 million. Structure Therapeutics plans to initiate a Phase 1 study for ACCG-2671, their oral amylin receptor agonist, by year-end 2025.
Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic diseases, has announced its participation in two major healthcare investor conferences in June 2025:
- The Jefferies Global Healthcare Conference on June 5 at 8:10 a.m. ET in New York, featuring a fireside chat and one-on-one meetings
- The Goldman Sachs Global Healthcare Conference on June 11 at 10:40 a.m. ET in Miami, also including a fireside chat and one-on-one meetings
Both fireside chat sessions will be available via webcast on the company's investor relations website, with replays accessible for 90 days.
Structure Therapeutics (NASDAQ: GPCR) announced completion of enrollment for its aleniglipron obesity treatment studies ACCESS and ACCESS II, with topline data expected by year-end 2025. The studies, involving over 300 patients, will evaluate doses up to 240mg with optimized titration regiments.
The company reported strong financials with $883.5 million in cash and investments, expected to fund operations through 2027. R&D expenses increased to $108.8 million for 2024, up from $70.1 million in 2023. Net loss for 2024 was $122.5 million.
Structure Therapeutics is advancing its oral small molecule obesity portfolio, including ACCG-2671, an oral amylin receptor agonist expected to begin Phase 1 trials by year-end 2025. The company also maintains pipeline programs targeting GIPR, GCGR, and APJR for obesity treatment.